Advanced c-myc Antisense (AVI-4126)-Eluting Phosphorylcholine-Coated Stent Implantation Is Associated with Complete Vascular Healing and Reduced Neointimal Formation in the Porcine Coronary Restenosis Model

Catheterization and Cardiovascular Interventions

Volumn 61, Issue 4, 2004, Pages 518-527

  Kipshidze, Nicholas N ^a,e   Iversen, Patrick ^b   Kim, Han Soo ^c   Yiazdi, Hamid ^c   Dangas, George ^a   Seaborn, Rufus ^c   New, Gishel ^a   Tio, Fermin ^d   Waksman, Ron ^c   Mehran, Roxana ^a   Tsapenko, Mykola ^a   Stone, Gregg W ^a   Roubin, Gary S ^a   Iyer, Sriram ^a   Leon, Martin B ^a   Moses, Jeffrey W ^a  

^a CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^b AVI BIOPHARMA INC   (United States)

^c Research Inst   (United States)

^d SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

^e LENOX HILL HEART AND VASCULAR INSTITUTE   (United States)

Author keywords

Drug eluting stent; Gene therapy; Restenosis

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; AVI 4126; C MYC ANTISENSE OLIGONUCLEOTIDE; MYC PROTEIN; PHOSPHORYLCHOLINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; DRUG ELUTING STENT; ELECTRON MICROSCOPY; FEMALE; HEALING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INTIMA; MALE; MORPHOMETRICS; NONHUMAN; PROTEIN EXPRESSION; RESTENOSIS; SWINE; WESTERN BLOTTING;

ANIMALS; BLOOD VESSEL PROSTHESIS IMPLANTATION; COATED MATERIALS, BIOCOMPATIBLE; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; CORONARY VESSELS; DISEASE MODELS, ANIMAL; FEMALE; FOLLOW-UP STUDIES; MALE; MODELS, CARDIOVASCULAR; MORPHOLINES; PHOSPHORYLCHOLINE; PROTO-ONCOGENE PROTEINS C-MYC; STATISTICS; STENTS; SWINE; TREATMENT OUTCOME; TUNICA INTIMA;

EID: 12144288392     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.20007     Document Type: Article

References (29)

1. Speir E, Epstein SE. Inhibition of smooth muscle cell proliferation by an antisense oligodeoxynucleotide targeting the messenger RNA encoding proliferating cell nuclear antigen. Circulation 1992;86:538-547.
2. Simons M, Edelman ER, DeKeyser JL, et al. Antisense c-myb oligonucleotides inhibit arterial smooth muscle cell accumulation in vivo. Nature 1992;359:67-70.
3. Gunn J, Holt CM, Francis SE, et al. The effect of oligonucleotides to c-myb on vascular smooth muscle cell proliferation and neo-intima formation after porcine coronary angioplasty. Circ Res 1997;80:520-531.
4. Zalewski A, Shi Y, Mannion JD, et al. Synthetic DNA-based compounds for the prevention of coronary restenosis. In: Eric Wickstrom, editor. Current status and future challenges in clinical trials of genetic therapy with antisense DNA and DNA vectors. New York: Marcel Dekker; 1998. p 363-393.
5. Kutryk MJ, Foley DP, van den Brand M, Hamburger JN, van der Giessen WJ, deFeyter PJ, Bruining N, Sabate M, Serruys PW. Local intracoronary administration of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis: results of the randomized investigation by the Thoraxcenter of antisense DNA using local delivery and IVUS after coronary stenting (ITALICS) trial. J Am Coll Cardiol 2002;39:281-287.
6. Stein C, Cheng Y. Antisense oligonucleotides as therapeutic agents: is the bullet really magical? Science 1993;261;1004-1012.
7. Shocman RL, Hartig R, Huang Y, et al. Fluorescence microscopic comparison of the binding of phosphodiester and phosphothioate oligodeoxyribonucleotides to subcellular structures, including intermediate filaments, the endoplasmic reticulum and the nuclear interior. Antisense Nucl Acid Dev 1997;7:291.
8. Hudziak RM, Barofsky E, Barofsky DF, et al. Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation. Antisense Nucl Acid Drug Dev 1996;6:267-272.
9. Hudziak RM, Summerton J, Weller DD, et al. Antiproliferative effects of steric blocking phosphorodiamidate morpholino antisense agents directed against c-myc. Antisense Nucl Acid Drug Dev 2000;10:163-176.
10. Arora V, Knapp DC, Smith BL, et al. c-myc antisense limits rat liver regeneration and indicates role for c-myc in regulating cytochrome P-450 3A Activity. J Pharmacol Exptl Ther 2000;292: 921-928.
11. Summerton J, Stein D, Huang B, et al. Morpholino and phosphorothioate antisense oligomers compared in cell-free and in-cell systems. Antisense Nucl Acid Drug Dev 1997;7:63-75.
12. Taylor MF, Paulaskis JD, Weller DD, et al. In vivo efficacy of morpholino modified oligomers directed against tumor necrosis factor-a mRNA. J Biol Chem 1996;29:17452-17455.
13. Kipshidze N, Keane D, Stein D. Local delivery of c-myc neutrally charged antisense oligonucleotides with transport catheter inhibits myointimal hyperplasia and positively affects vascular remodeling in the rabbit balloon injury model. Catheter Cardvac Interv 2001; 54:247-256.
14. Summerton J, Weller D. Morpholino antisense oligomers: design, preparation and properties. Antisense Nucl Acid Drug Dev 1997; 7:63-70.
15. Kornowski R, Hong MK, Tio FO, et al. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol 1998;31:224-230.
16. Sheppard R, Eisenberg MJ. Intracoronary readiotherapy for restenosis. N Engl J Med 2001;344:295-297.
17. Kipshidze N, Iversen P, Keane E, et al. Complete vascular healing and sustained suppression of neointimal thickening after local delivery of advanced c-myc antisense at six months follow-up in a rabbit balloon injury model. Cardiovasc Radiat Med 2002;3:26-30.
18. Suzuki T, Kopia G, Hayashi S, et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001;104:1188-1193.
19. Herdeg C, Oberhoff M, Baumbach A, et al. Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo. J Am Coll Cardiol 2000;35:1969-1976.
20. Farb A, Heller Phillip F, Shroff S, et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 2001;104:473-479.
21. Heldman AW, Cheng L, Jenkins GM, Heller PF, et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 2001;103: 2289-2295.
22. Sousa JE, Costa MA, Abizaid A, et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2001;103: 192-195.
23. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780.
24. Stone GW, Ellis SG, Cox DA, et al. A polymer-based paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-231.
25. Moses JW, Leon MB, Popma J, et al. Angiographic and clinical outcomes after a sirolimus-eluting stent compared to a standard stent in patients with native coronary artery stenoses. N Eng J Med 2003;349:1315-1323.
26. Grube E, Bullesfeld L. Initial experience with paclitaxel-coated stents. J Interv Cardiol 2002;15:471-475.
27. Carter AJ, Bailey LR, Llanos G, et al. Stent based sirolimus delivery reduces neointimal proliferation in a porcine coronary model of restenosis. J Am Coll Cardiol 2000;35:13A.
28. Sousa JE, Costa MA, Sousa AG, et al. Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries. Circulation 2003;107: 381-383.
29. Edelman ER, Simons M, Sirois MG, et al. c-myc in vasculoproliferative disease. Circ Res 1995;76:176-182.